Lymphoma & Plasma Cell Disorders
Article
Bendamustine-Based Salvage Regimen Offers Hope
New research suggests salvage therapy may have better survival results than palliative care for patients with lymphoma.
News
Treatment simulation could help personalize myeloma therapy
A simulation helped identify whether patients would benefit most from treatment with bortezomib or lenalidomide.
News
Promising phase 3 results for ixazomib in multiple myeloma
The drug met the primary endpoint in a phase 3 study of maintenance therapy after stem cell transplant.
Conference Coverage
Is CLL chemoimmunotherapy dead? Not yet
CHICAGO – Frontline use of chemoimmunotherapy is complicated.
News
FDA grants regular approval to venetoclax for CLL/SLL
The drug is indicated for patients with CLL or SLL, with or without 17p deletion, who have had at least one prior therapy.
Conference Coverage
Ruxolitinib overcame lenalidomide resistance in myeloma
The clinical trial is the first to demonstrate the activity of a JAK inhibitor in the treatment of myeloma patients.
News
CAR T therapy to enter early testing in multiple myeloma
The phase 1b/2 trial will begin enrollment in the second half of 2018.
Article
Sorafenib Improves Survival for Patients With Rare Sarcomas
Results from a phase 3 trial show positive survival outcomes in patients with desmoid tumors who take a kinase inhibitor than that of those...
News
FDA places partial hold on trials after secondary lymphoma
A pediatric patient developed a secondary T-cell lymphoma during a phase 1 trial of tazemetostat.
News
PDPK1 could be novel target in MCL
The poor prognosis of mantle cell lymphoma despite advances in immunochemotherapy means that new therapeutic targets are needed.
